SI3630098T1 - Kombinacija antagonista receptorja 5-HT6 in zaviralca acetilholinesteraze za uporabo pri zdravljenju Alzheimerjeve bolezni pri podpulaciji pacientov, ki nosijo alele ApoE4 - Google Patents
Kombinacija antagonista receptorja 5-HT6 in zaviralca acetilholinesteraze za uporabo pri zdravljenju Alzheimerjeve bolezni pri podpulaciji pacientov, ki nosijo alele ApoE4Info
- Publication number
- SI3630098T1 SI3630098T1 SI201830258T SI201830258T SI3630098T1 SI 3630098 T1 SI3630098 T1 SI 3630098T1 SI 201830258 T SI201830258 T SI 201830258T SI 201830258 T SI201830258 T SI 201830258T SI 3630098 T1 SI3630098 T1 SI 3630098T1
- Authority
- SI
- Slovenia
- Prior art keywords
- alzheimer
- disease
- treatment
- combination
- receptor antagonist
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201700313 | 2017-05-24 | ||
| DKPA201700538 | 2017-09-29 | ||
| PCT/EP2018/063402 WO2018215478A1 (en) | 2017-05-24 | 2018-05-22 | Combination of a 5-ht6 receptor antagonist and an acetylcholinesterase inhibitor for use in the treatment of alzheimer's disease in a patient subpopulation carrying apoe4 alleles |
| EP18726791.9A EP3630098B1 (en) | 2017-05-24 | 2018-05-22 | Combination of a 5-ht6 receptor antagonist and an acetylcholinesterase inhibitor for use in the treatment of alzheimer's disease in a patient subpopulation carrying apoe4 alleles |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI3630098T1 true SI3630098T1 (sl) | 2021-07-30 |
Family
ID=62235961
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201830258T SI3630098T1 (sl) | 2017-05-24 | 2018-05-22 | Kombinacija antagonista receptorja 5-HT6 in zaviralca acetilholinesteraze za uporabo pri zdravljenju Alzheimerjeve bolezni pri podpulaciji pacientov, ki nosijo alele ApoE4 |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US11464759B2 (sl) |
| EP (1) | EP3630098B1 (sl) |
| JP (1) | JP7167065B2 (sl) |
| KR (1) | KR20200007795A (sl) |
| CN (1) | CN111032038A (sl) |
| AU (1) | AU2018272883B2 (sl) |
| BR (1) | BR112019001145A2 (sl) |
| CA (1) | CA3063968A1 (sl) |
| CY (1) | CY1124282T1 (sl) |
| DK (1) | DK3630098T3 (sl) |
| ES (1) | ES2869128T3 (sl) |
| HR (1) | HRP20210634T1 (sl) |
| HU (1) | HUE053636T2 (sl) |
| LT (1) | LT3630098T (sl) |
| MX (1) | MX2019013912A (sl) |
| PL (1) | PL3630098T3 (sl) |
| PT (1) | PT3630098T (sl) |
| RS (1) | RS61704B1 (sl) |
| SG (1) | SG11201909895UA (sl) |
| SI (1) | SI3630098T1 (sl) |
| WO (1) | WO2018215478A1 (sl) |
| ZA (1) | ZA201907525B (sl) |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002303094B2 (en) | 2001-03-29 | 2006-11-23 | Eli Lilly And Company | N-(2-arylethyl)benzylamines as antagonists of the 5-HT6 receptor |
| PT1529116E (pt) * | 2002-08-07 | 2009-09-10 | Novartis Ag | Métodos para o tratamento da demência com base no genótipo da apo e |
| EP2937085B1 (en) | 2007-05-22 | 2019-07-10 | Otsuka Pharmaceutical Co., Ltd. | A medicament comprising a carbostyril derivative and donezepil for treating alzheimer's disease |
| EP2508177A1 (en) | 2007-12-12 | 2012-10-10 | Glaxo Group Limited | Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline |
| RU2369600C1 (ru) | 2008-01-24 | 2009-10-10 | Андрей Александрович Иващенко | ЗАМЕЩЕННЫЕ 4-СУЛЬФОНИЛ-ПИРАЗОЛЫ И 3-СУЛЬФОНИЛ-ПИРАЗОЛО[1,5-a]ПИРИМИДИНЫ - АНТАГОНИСТЫ СЕРОТОНИНОВЫХ5-HT6 РЕЦЕПТОРОВ, АКТИВНЫЙ КОМПОНЕНТ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ЛЕКАРСТВЕННОЕ СРЕДСТВО И СПОСОБЫ ИХ ПОЛУЧЕНИЯ |
| JP2012523437A (ja) | 2009-04-13 | 2012-10-04 | セラヴァンス， インコーポレーテッド | 認知障害の治療のための５−ｈｔ４受容体アゴニスト化合物 |
| JO3459B1 (ar) | 2012-09-09 | 2020-07-05 | H Lundbeck As | تركيبات صيدلانية لعلاج مرض الزهايمر |
| US20160038484A1 (en) * | 2013-04-03 | 2016-02-11 | The University Of Utah Research Foundation | Application of 5-ht6 receptor antagonists for the alleviation of cognitive deficits of down syndrome |
| WO2016179569A1 (en) * | 2015-05-07 | 2016-11-10 | Axovant Sciences Ltd. | Compositions and methods of treating a neurodegenerative disease |
| DK3448430T3 (da) * | 2016-04-26 | 2023-07-03 | H Lundbeck As | Anvendelse af en acetylcholinesterase-inhibitor og idalopirdin til reduktion af fald hos patienter med parkinsons sygdom |
| US10864191B2 (en) * | 2016-05-11 | 2020-12-15 | H. Lundbeck A/S | 5-HT6 receptor antagonists for use in the treatment of Alzheimer's disease with apathy as comorbidity |
-
2018
- 2018-05-22 BR BR112019001145-5A patent/BR112019001145A2/pt active Search and Examination
- 2018-05-22 PL PL18726791T patent/PL3630098T3/pl unknown
- 2018-05-22 SI SI201830258T patent/SI3630098T1/sl unknown
- 2018-05-22 SG SG11201909895U patent/SG11201909895UA/en unknown
- 2018-05-22 KR KR1020197032218A patent/KR20200007795A/ko active IP Right Grant
- 2018-05-22 DK DK18726791.9T patent/DK3630098T3/da active
- 2018-05-22 CA CA3063968A patent/CA3063968A1/en active Pending
- 2018-05-22 WO PCT/EP2018/063402 patent/WO2018215478A1/en active Application Filing
- 2018-05-22 JP JP2019564834A patent/JP7167065B2/ja active Active
- 2018-05-22 ES ES18726791T patent/ES2869128T3/es active Active
- 2018-05-22 CN CN201880033314.8A patent/CN111032038A/zh active Pending
- 2018-05-22 EP EP18726791.9A patent/EP3630098B1/en active Active
- 2018-05-22 PT PT187267919T patent/PT3630098T/pt unknown
- 2018-05-22 LT LTEP18726791.9T patent/LT3630098T/lt unknown
- 2018-05-22 MX MX2019013912A patent/MX2019013912A/es unknown
- 2018-05-22 RS RS20210449A patent/RS61704B1/sr unknown
- 2018-05-22 AU AU2018272883A patent/AU2018272883B2/en active Active
- 2018-05-22 HU HUE18726791A patent/HUE053636T2/hu unknown
- 2018-05-23 US US15/987,449 patent/US11464759B2/en active Active
-
2019
- 2019-11-13 ZA ZA2019/07525A patent/ZA201907525B/en unknown
-
2021
- 2021-04-14 CY CY20211100328T patent/CY1124282T1/el unknown
- 2021-04-22 HR HRP20210634TT patent/HRP20210634T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20200007795A (ko) | 2020-01-22 |
| PL3630098T3 (pl) | 2021-09-06 |
| RU2019135609A3 (sl) | 2021-08-23 |
| CA3063968A1 (en) | 2018-11-29 |
| AU2018272883B2 (en) | 2024-02-15 |
| DK3630098T3 (da) | 2021-04-26 |
| ZA201907525B (en) | 2022-02-23 |
| WO2018215478A1 (en) | 2018-11-29 |
| RU2019135609A (ru) | 2021-06-24 |
| MX2019013912A (es) | 2020-01-21 |
| CY1124282T1 (el) | 2022-07-22 |
| US20180353477A1 (en) | 2018-12-13 |
| EP3630098B1 (en) | 2021-03-24 |
| JP2020520964A (ja) | 2020-07-16 |
| LT3630098T (lt) | 2021-05-25 |
| BR112019001145A2 (pt) | 2019-04-30 |
| AU2018272883A1 (en) | 2019-11-14 |
| RS61704B1 (sr) | 2021-05-31 |
| ES2869128T3 (es) | 2021-10-25 |
| HUE053636T2 (hu) | 2021-07-28 |
| JP7167065B2 (ja) | 2022-11-08 |
| US11464759B2 (en) | 2022-10-11 |
| CN111032038A (zh) | 2020-04-17 |
| PT3630098T (pt) | 2021-04-21 |
| HRP20210634T1 (hr) | 2021-05-28 |
| EP3630098A1 (en) | 2020-04-08 |
| SG11201909895UA (en) | 2019-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3577135T3 (pl) | Kompozycja farmaceutyczna do stosowania do leczenia lub zapobiegania chorobom związanym z c5 | |
| IL274578A (en) | Pharmaceutical compounds and preparations thereof for use in the treatment of leiftic diseases | |
| GB201917974D0 (en) | Apparatus and system for measuring one or more parameters of a person's foot | |
| PH12017502099A1 (en) | Methods for diagnosing and assessing treatment for cushing's syndrome | |
| IL264040A (en) | An oxazine derivative for use in the prevention of alzheimer's disease in at risk patients | |
| IL284175A (en) | Dosing regimens in the use of LY3154207 in the treatment of diseases of the dopaminergic central nervous system | |
| IL262546B (en) | Use of an acetylcholinesterase inhibitor and idalopyridine to reduce falls in Parkinson's patients | |
| EP3578094A4 (en) | PROCESS FOR DETERMINING THE CORONARY STATUS OF A PERSON, AND USE OF THIS TO CONTROL AND PREVENT THE RISK OF DEVELOPING CARDIOVASCULAR DISEASES | |
| PL3937948T3 (pl) | Fitoekdyzony i ich pochodne do ich zastosowania w leczeniu chorób nerwowo-mięśniowych | |
| ZA201907525B (en) | Combination of a 5-ht6 receptor antagonist and an acetylcholinesterase inhibitor for use in the treatment of alzheimer's disease in a patient subpopulation carrying apoe4 alleles | |
| IL272495A (en) | Pharmaceutical compounds and preparations thereof for use in the treatment of leiftic diseases | |
| PT3600276T (pt) | Beta-histina, ou um seu sal farmaceuticamente aceitável, e um inibidor da monoamina oxidase, para utilização no tratamento ou prevenção de um ou mais sintomas de vertigem num indivíduo | |
| MX2018000947A (es) | Marcadores geneticos asociados con la respuesta a los antagonistas del receptor crth2. | |
| SG11201406093VA (en) | An h3 receptor antagonist for use in the treatment of alzheimer's disease | |
| LT3413870T (lt) | Igmesinas, skirtas panaudoti alzheimerio ligos gydymui | |
| MX2017017155A (es) | Antagonistas del receptor de tromboxano en erea/asma. | |
| IL267716A (en) | Drug combination therapies that use drugs designed for bone and bone-related diseases | |
| SG11202000193UA (en) | Screening platform to identify therapeutic drugs or agents for treatment of alzheimer's disease | |
| GB201712742D0 (en) | Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases | |
| GB201509963D0 (en) | Apparatus for use in the care of a person's body |